Imaging Advancements in Nuclear Medicine: Pancreatic Neuroendocrine Tumor Localization and Treatment.

Background This case report details a 57-year-old African American man with pancreatic neuroendocrine tumors (NETs). The patient underwent positron emission tomography (PET) imaging using gallium Ga 68 dotatate, which localized the tumors. Selected tumors were treated with 4 doses of 200 mCi of lute...

Full description

Bibliographic Details
Published in:Radiologic Technology Vol. 93; no. 5; pp. 431 - 437
Main Authors: Palmer Stephens, Chelsea, Street Beam, Asher, Gray, Zack, Mansfield, Julia, Reves, Lexie, Gray, Jennie, Stamey, Alexa, Collum, Matthew, Vijayakumar, Vani
Format: case study diagnostic images tables/charts Journal Article
Published: American Society of Radiologic Technologists May/Jun2022
Online Access:View this record in EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=156500254&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 156500254
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        00338397
        39J
      jtl: Radiologic Technology
      issn: 00338397
      maglogo: N
    pubinfo:
      dt: May/Jun2022
      vid: 93
      iid: 5
      pid: 7052
      pub: American Society of Radiologic Technologists
      place: Alburquerque, New Mexico
    artinfo:
      ui:
        156500254
        156500254
        156500254
        156500254
      ppf: 431
      ppct: 6
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: Imaging Advancements in Nuclear Medicine: Pancreatic Neuroendocrine Tumor Localization and Treatment.
      aug:
        au:
          Palmer Stephens, Chelsea
          Street Beam, Asher
          Gray, Zack
          Mansfield, Julia
          Reves, Lexie
          Gray, Jennie
          Stamey, Alexa
          Collum, Matthew
          Vijayakumar, Vani
        affil: Director of the Master of Science in Nuclear Medicine Technology program and assistant professor for the Department of Clinical and Diagnostic Sciences at the University of Mississippi Medical Center, School of Health Related Professions in Jackson
      sug:
        subj:
          Pancreatic Neoplasms Radiography
          Neuroendocrine Tumors Radiography
          Pancreatic Neoplasms Radiotherapy
          Neuroendocrine Tumors Radiotherapy
          Nuclear Medicine
          Organometallic Compounds Therapeutic Use
          Treatment Outcomes
          Male
          Middle Age
          Positron-Emission Tomography Methods
          Gallium Diagnostic Use
          Radiopharmaceuticals Therapeutic Use
          Pancreatectomy
          Splenectomy
          Mesenteric Veins Surgery
          Neuroendocrine Tumors Symptoms
          Pancreatic Neoplasms Symptoms
          Middle Aged: 45-64 years
          Male
      ab: Background This case report details a 57-year-old African American man with pancreatic neuroendocrine tumors (NETs). The patient underwent positron emission tomography (PET) imaging using gallium Ga 68 dotatate, which localized the tumors. Selected tumors were treated with 4 doses of 200 mCi of lutetium Lu 177 dotatate during a period of 8 months. At the conclusion of treatment, the patient demonstrated improvement, progressing from bedbound and confused to ambulatory and coherent. In addition, the patient stated he felt no adverse effects. Discussion Pancreatic NETs are rare tumors affecting 0.001% of the population. These tumors are associated with various symptoms and are classified as functional or nonfunctional. Imaging modalities, such as computed tomography (CT), magnetic resonance (MR) imaging, and gallium Ga 68--labeled PET, are essential in detecting and evaluating pancreatic NETs. For patients with localized NETs, the primary treatment is surgery; however, the radiopharmaceuticals yttrium Y 90 microspheres and lutetium Lu 177 dotatate are used as therapy to treat nonresectable tumors. Conclusion Lutetium Lu 177 dotatate is used in NET cases that are deemed inoperable and for patients who are not responding to treatment. This case study demonstrates the effectiveness of combining imaging with Ga 68--labeled PET and treatment with lutetium Lu 177 dotatate. This treatment is not a cure but has been shown to improve a patient's quality of life.
      pubtype: Academic Journal
      doctype:
        case study
        diagnostic images
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N